We provide you with 20 years of free, institutional-grade data for AVDL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AVDL. Explore the full financial landscape of AVDL stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Seurer Jerad G. | Initial | 2024-05-03 |
The information provided in this report about AVDL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Avadel Pharmaceuticals plc(NASDAQ:AVDL) 
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. T...
Website: http://www.avadel.com
Founded: 1990
Full Time Employees: 50
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic